• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of glaucoma >Use of a Collagen Matrix Implant as an Adjuvant in Combined Surgery Involving Phacoemulsification and Nonpenetrating Deep Sclerectomy
【24h】

Use of a Collagen Matrix Implant as an Adjuvant in Combined Surgery Involving Phacoemulsification and Nonpenetrating Deep Sclerectomy

机译：在组合手术中使用胶原基质植入物作为辅助手术，涉及沉乳化乳化和非持久的巩膜切除术

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To assess the efficacy and safety of the Ologen collagen matrix as an adjuvant for combined phacoemulsification and nonpenetrating deep sclerectomy (Phaco-NPDS), in addition to mitomycin C (MMC). Materials and Methods: This was a longitudinal retrospective comparative study of eyes treated with Phaco-NPDS, with (group 1) or without (group 2) an Ologen collagen matrix implant, in addition to MMC. The main outcome measures were operative success [absolute success: intraocular pressure (IOP) <18 mm Hg and an at least 20% reduction from baseline without medication; relative success: IOP<18 mm Hg and at least 20% reduction from baseline IOP with or without medication], mean reductions (%) in IOP and medication use; number of postoperative reinterventions (goniopuncture, needling, reoperation), and number of complications. Results: The mean age of the study population (N=100) was 72.0 +/- 9.7 years. Groups 1 (n=51) and 2 (n=49) achieved absolute success rates of 72.5% and 55.1%, respectively (P=0.054), and relative success rates of 90.2% and 83.7%, respectively (P=0.251). From a similar baseline IOP (19.8 and 20.7 mm Hg in groups 1 and 2, respectively, P=0.527), eyes in group 1 achieved a significant lower 12-month IOP (11.7 vs. 14.5 mm Hg, respectively, P=0.002) and a lower rate of medication use (0.2 vs. 0.9, respectively, P<0.001). Eyes in group 2 presented with a higher rate of bleb failure (12.2% vs. 2.0%, P=0.028), leading to a higher rate of needling procedures (38.8% vs. 2.0%, P<0.001) during the postoperative period. Conclusions: The adjunctive use of Ologen collagen matrix in addition to MMC during Phaco-NPDS was associated with a higher rate of absolute success, a lower mean IOP at 12 months, a lower rate of bleb failure, and a lower rate of postoperative bleb needling.
机译：目的：除了丝霉素C（MMC）之外，还评估渗透胶原基质作为佐剂的佐剂和非旋转肌切除术（Phaco-NPDS）的疗效和安全性。材料和方法：这是用Phaco-NPDS治疗的眼睛的纵向回顾性对比研究，除MMC之外，（第1组）或没有（第2组）型胶原基质植入物。主要结果措施是可操作的成功[绝对成功：从没有药物的基线减少18 mm Hg的眼压（IOP）<18 mm Hg;相对成功：IOP <18毫米HG，从基线IOP减少至少20％，IOP和药物使用的平均降低（％）;术后重新融合的数量（Goniopuncture，针刺，重新组合）和并发症的数量。结果：研究人群的平均年龄（n = 100）是72.0 +/- 9.7岁。第1组（n = 51）和2（n = 49）达到了72.5％和55.1％的绝对成功率（p = 0.054），相对成功率分别为90.2％和83.7％（P = 0.251）。从类似的基线IOP（19.8和20.7mm Hg，分别为p = 0.527），第1组中的眼睛达到了显着的12个月IOP（分别为11.7毫米，P = 0.002）和较低的药物使用率（分别为0.2 vs.0.9，p <0.001）。第2组中的眼睛呈现出较高的BLEB失败率（12.2％与2.0％，P = 0.028），导致术后期间的针刺程序（38.8％vs.2.0％，P <0.001）率较高。结论：耐药胶原基质除MMC外，耐磷酸盐癌的辅助用途与较高的绝对成功率有关，12个月的平均IOP较低，较低的填料衰竭率，术后较低的术语钻孔针刺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号